Summit’s sialorrhoea candidate moves into Ph II
Oxford-based biotechnology group Summit plc has kicked off a Phase II trial investigating the potential of its lead drug candidate SMT D001 as a treatment of sialorrhoea.
Read MoreAuthor: Selina McKee
Report indicates antidepressants publication bias
Research putting antidepressants in a positive light is more likely to make it into medical journals than that with negative outcomes, suggests a report in the New England Journal of Medicine.
Read MorePfizer snaps up Scil’s growth factor for $250m
Clearly demonstrating its hunger for biotech again, Pfizer has agreed to shell out $250 million for the worldwide rights to private German company Scil Technology’s growth factor CD-RAP.
Read MoreNovartis Q4 profit plummets on restructuring hit
Swiss drug giant Novartis saw its fourth-quarter net profit tumble 42% to £931 million, falling below analysts’ expectations, as restructuring costs and skinny US sales ate into earnings.
Read MoreNHS Alliance addresses integrated health services
The NHS Alliance has called on several organisations to pull together to help clinicians lead the looming integration of primary and secondary healthcare services.
Read More
